216 related articles for article (PubMed ID: 15102757)
21. Intranasal immunisation of mice with a streptococcal peptide-based vaccine.
Relf W; Hayman W; Russell-Jones G; Good M
Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788
[No Abstract] [Full Text] [Related]
22. Sortase A induces Th17-mediated and antibody-independent immunity to heterologous serotypes of group A streptococci.
Fan X; Wang X; Li N; Cui H; Hou B; Gao B; Cleary PP; Wang B
PLoS One; 2014; 9(9):e107638. PubMed ID: 25232948
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.
Childers NK; Miller KL; Tong G; Llarena JC; Greenway T; Ulrich JT; Michalek SM
Infect Immun; 2000 Oct; 68(10):5509-16. PubMed ID: 10992447
[TBL] [Abstract][Full Text] [Related]
24. Co-Activation of Th17 and Antibody Responses Provides Efficient Protection against Mucosal Infection by Group A Streptococcus.
Chen X; Li N; Bi S; Wang X; Wang B
PLoS One; 2016; 11(12):e0168861. PubMed ID: 28030629
[TBL] [Abstract][Full Text] [Related]
25. Remote glucosyltransferase-microparticle vaccine delivery induces protective immunity in the oral cavity.
Smith DJ; Lam A; Barnes LA; King WF; Peacock Z; Wise DL; Trantolo DJ; Taubman MA
Oral Microbiol Immunol; 2003 Aug; 18(4):240-8. PubMed ID: 12823800
[TBL] [Abstract][Full Text] [Related]
26. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
[TBL] [Abstract][Full Text] [Related]
27. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
28. Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate.
McNeilly C; Cosh S; Vu T; Nichols J; Henningham A; Hofmann A; Fane A; Smeesters PR; Rush CM; Hafner LM; Ketheesan N; Sriprakash KS; McMillan DJ
PLoS One; 2016; 11(6):e0156639. PubMed ID: 27310707
[TBL] [Abstract][Full Text] [Related]
29. Immunogenic characterization and protection against Streptococcus mutans infection induced by intranasal DNA prime-protein boost immunization.
Li YH; Huang S; Du M; Bian Z; Chen Z; Fan MW
Vaccine; 2010 Jul; 28(32):5370-6. PubMed ID: 20573581
[TBL] [Abstract][Full Text] [Related]
30. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.
Dale JB
Vaccine; 1999 Jan; 17(2):193-200. PubMed ID: 9987154
[TBL] [Abstract][Full Text] [Related]
31. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections.
Dale JB; Chiang EC
J Infect Dis; 1995 Apr; 171(4):1038-41. PubMed ID: 7706785
[TBL] [Abstract][Full Text] [Related]
32. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
Xue G; Yu L; Li S; Shen X
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):202-10. PubMed ID: 19912341
[TBL] [Abstract][Full Text] [Related]
33. Protective immunity evoked by locally administered group A streptococcal vaccines in mice.
Bronze MS; McKinsey DS; Beachey EH; Dale JB
J Immunol; 1988 Oct; 141(8):2767-70. PubMed ID: 3049817
[TBL] [Abstract][Full Text] [Related]
34. Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice.
Dunn LA; McMillan DJ; Batzloff M; Zeng W; Jackson DC; Upcroft JA; Upcroft P; Olive C
Vaccine; 2002 Jun; 20(21-22):2635-40. PubMed ID: 12034087
[TBL] [Abstract][Full Text] [Related]
35. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
[TBL] [Abstract][Full Text] [Related]
36. Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization.
Wu HY; Nikolova EB; Beagley KW; Eldridge JH; Russell MW
Infect Immun; 1997 Jan; 65(1):227-35. PubMed ID: 8975916
[TBL] [Abstract][Full Text] [Related]
37. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
[TBL] [Abstract][Full Text] [Related]
38. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
[TBL] [Abstract][Full Text] [Related]
39. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
40. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
